Related Experiment Videos
Prospective clinical trial of a human tumor cloning system
Abstract:
A prospective clinical trial was performed to evaluate the usefulness of a human tumor cloning system for selecting single-agent chemotherapy for patients with advanced cancers. Six hundred four single-agent trials were performed in the 470 patients whose tumors were submitted for drug sensitivity testing. Only 246 of these 604 trials (41%) could be directed by the cloning system results because of inadequate tumor growth and other difficulties. In these 246 prospective trials, there was a 60% true positive and an 85% true negative rate for predicting for response or lack of response of an individual patient's tumor to the single agent. There was also a relationship between the percentage of decrease in survival of tumor colony-forming units and the probability of a clinical response of the patient's tumor to the same drug used in vivo. Despite these encouraging findings, work to improve tumor growth and additional prospective clinical trials of the system are needed before the system can be recommended for routine clinical use.
Insights
This study assessed a human tumor cloning system for chemotherapy selection in advanced cancers. While showing promise with 60% true positive rates, further research is needed for routine clinical use.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Selecting effective single-agent chemotherapy for advanced cancers remains a challenge.
- Predictive assays for drug sensitivity can improve patient outcomes.
Purpose of the Study:
- To evaluate the clinical utility of a human tumor cloning system for guiding single-agent chemotherapy selection in advanced cancer patients.
Main Methods:
- A prospective clinical trial involving 470 patients with advanced cancers.
- Drug sensitivity testing using a human tumor cloning system for 604 single-agent chemotherapy trials.
- Analysis of the system's predictive accuracy (true positive/negative rates) and correlation with clinical response.
Main Results:
- The cloning system successfully guided chemotherapy selection in 41% of cases (246/604) due to technical limitations.
- The system demonstrated a 60% true positive and 85% true negative rate in predicting patient response to chemotherapy.
- A correlation was observed between reduced tumor colony-forming units and clinical response to the tested agent.
Conclusions:
- The human tumor cloning system shows potential for predicting chemotherapy response in advanced cancers.
- Improvements in tumor growth and further prospective trials are necessary before routine clinical adoption.
- The system's predictive accuracy warrants continued investigation for personalized cancer treatment.